Boothbay Fund Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Boothbay Fund Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-30,600	Closed	-$14.2M	–	1938
2024 Q3	$14.2M	Buy	+30,600	New	+$14.7M	0.32%	39
2021 Q2	–	Sell	-235	Closed	-$5.05M	–	2140
2021 Q1	$5.05M	Buy	+235	New	+$51.6K	0.19%	98
2019 Q2	–	Sell	-42	Closed	-$773K	–	908
2019 Q1	$773K	Sell	42 -244	-85%	-$45.1K	0.07%	287
2018 Q4	$4.74M	Buy	+286	New	+$49.6K	0.69%	25
2016 Q3	–	Sell	-3,800	Closed	-$327K	–	812
2016 Q2	$327K	Buy	+3,800	New	+$328K	0.13%	226

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Boothbay Fund Management's VRTX Position: Q1 2026 in Review

Boothbay Fund Management opened a new position in Vertex Pharmaceuticals (VRTX) in Q1 2026: 1,320 shares worth $589K. The stake represents 0.01% of the portfolio and ranks #1255 among its holdings. This is a return to the name: Boothbay Fund Management previously reported a position in VRTX as recently as Q3 2025.

Boothbay Fund Management first reported a position in VRTX in Q1 2017 and has held it in 16 quarters since. The position peaked at $2.95M in Q4 2021. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Boothbay Fund Management held 1,320 shares of Vertex Pharmaceuticals worth $589K as of Q1 2026.
Vertex Pharmaceuticals was a new Boothbay Fund Management position in Q1 2026.
Vertex Pharmaceuticals made up 0.01% of Boothbay Fund Management's portfolio in Q1 2026, its #1255 holding.
Boothbay Fund Management first reported a position in Vertex Pharmaceuticals in Q1 2017 and has held it in 16 quarters since.
Boothbay Fund Management's Vertex Pharmaceuticals position peaked at $2.95M in Q4 2021.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Boothbay Fund Management's 13F filing for Q1 2026, filed 15 May 2026.